Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide.
Sign Up to like & getrecommendations! Published in 2020 at "Pancreas"
DOI: 10.1097/mpa.0000000000001514
Abstract: FIGURE 1. A, Abdominal CT scan showing multiple liver metastases. B, Abdominal magnetic resonance imaging scan showing no evidence of liver metastases. W e report an extremely rare case of a metastatic VIPoma with insulin… read more here.
Keywords: cosecretion; response lanreotide; metastatic vipoma; complete response ... See more keywords
Capecitabine and temozolomide (CAPTEM) is effective in metastatic well‐differentiated gastrointestinal neuroendocrine tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Digestive Diseases"
DOI: 10.1111/1751-2980.13123
Abstract: The aim of this study was to investigate the outcomes and prognostic factors of patients with metastatic gastrointestinal neuroendocrine tumor (mGI‐NET) who were treated with capecitabine and temozolomide (CAPTEM) and somatostatin receptor ligand (octreotide or… read more here.
Keywords: temozolomide captem; gastrointestinal neuroendocrine; capecitabine temozolomide; captem effective ... See more keywords
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.01013
Abstract: PURPOSE Patients with advanced pancreatic neuroendocrine tumors (NETs) have few treatment options that yield objective responses. Retrospective and small prospective studies suggest that capecitabine and temozolomide are associated with high response rates (RRs) and long… read more here.
Keywords: capecitabine; capecitabine temozolomide; patients advanced; neuroendocrine tumors ... See more keywords
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2021.7017
Abstract: BACKGROUND The capecitabine/temozolomide (CAPTEM) regimen has significant activity in advanced neuroendocrine tumors (NETs). Questions exist regarding activity in pancreatic versus nonpancreatic NETs, risk of opportunistic infections, long-term myelotoxicity, and safety of prolonged treatment duration. Analysis… read more here.
Keywords: risk; analysis; capecitabine; months months ... See more keywords